Woodline Partners’s Alto Neuroscience ANRO Stock Holding History

Woodline Partners’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-359,873	Closed	-$777K	–	1076
2025 Q1	$777K	Sell	359,873 -262,103	-42%	-$938K	0.01%	787
2024 Q4	$2.63M	Buy	621,976 +496,976	+398%	+$3.1M	0.02%	610
2024 Q3	$1.43M	Hold	125,000	–	–	0.01%	493
2024 Q2	$1.34M	Hold	125,000	–	–	0.01%	445
2024 Q1	$1.92M	Buy	+125,000	New	+$1.96M	0.02%	427

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Woodline Partners's ANRO Position: Q2 2025 in Review

Woodline Partners sold out of Alto Neuroscience (ANRO) in Q2 2025, closing a stake of 359,873 shares — an estimated $777K sold.

Woodline Partners first reported a position in ANRO in Q1 2024 and held it in 5 quarters. The position peaked at $2.63M in Q4 2024. 80 funds tracked by Wall St. Rank hold ANRO as of Q2 2025.

Woodline Partners reported no remaining Alto Neuroscience position as of Q2 2025 after selling out during the quarter.
Woodline Partners sold 359,873 Alto Neuroscience shares in Q2 2025, an estimated $777K.
Woodline Partners first reported a position in Alto Neuroscience in Q1 2024 and held it in 5 quarters.
Woodline Partners's Alto Neuroscience position peaked at $2.63M in Q4 2024.
80 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.